Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Heparin, Enoxaparin and Rivaroxaban for VTE Prophylaxis in Moderate to Severe Traumatic Brain Injury
IRCT20230705058684N1Phase 2Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of heparin, enoxaparin and rivaroxaban in venous thromboembolism (VTE) and traumatic brain injury (TBI) (3 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Started Oct 2023; status: completed.
02
Drugs
heparinenoxaparinrivaroxaban
03
Conditions
venous thromboembolism (VTE)traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20230705058684N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230705058684N1.